论文部分内容阅读
目的 探讨骨肉瘤组织中P 糖蛋白 (P gp)、胎盘型谷胱甘肽 S 转移酶 (GST π)和DNA拓朴酶Ⅱ (TopoⅡ )的表达及其与预后的关系。方法 应用SP法检测P gp、GST π、TopoⅡ在 80例骨肉瘤中的表达 ,并应用COX比例风险模型评估它们对预后的影响。结果 80例骨肉瘤中P gp、GST π和TopoⅡ的表达率分别为 36 2 5 %、91 2 5 %和47 5 % ,其中P gp和TopoⅡ表达与WHO新分型和预后显著相关 (P <0 0 5 )。结论 P gp、GST π、和TopoⅡ等多因素联合作用是骨肉瘤多药耐药性 (multi drugresistance,MDR)的主要作用机制 ,并且P gp和TopoⅡ可能成为评估骨肉瘤预后的有价值的指标。
Objective To investigate the expression of P gp, GST π and Topo Ⅱ in osteosarcoma and its relationship with prognosis. Methods The expression of P gp, GST π and Topo Ⅱ in 80 cases of osteosarcoma was detected by SP method. The effect of COX proportional hazards model on the prognosis was evaluated. Results The expression rates of P gp, GST π and Topo Ⅱ were 36 2 5%, 91 2 5% and 47 5% respectively in 80 cases of osteosarcoma. The expressions of P gp and Topo Ⅱ were significantly correlated with the new type and prognosis of WHO (P < 0 0 5). Conclusions The combined effects of P gp, GST π and Topo Ⅱ are the main mechanisms of multidrug resistance (MDR) in osteosarcoma. P gp and Topo Ⅱ may be valuable prognostic indicators in osteosarcoma.